RU93048868A - METHOD FOR SAFE INTRODUCTION OF FATTY ACIDS, ITS APPLICATION FOR THE TREATMENT OF CANCER, INFECTIOUS VIRAL DISEASES AND OTHER DISORDERS - Google Patents

METHOD FOR SAFE INTRODUCTION OF FATTY ACIDS, ITS APPLICATION FOR THE TREATMENT OF CANCER, INFECTIOUS VIRAL DISEASES AND OTHER DISORDERS

Info

Publication number
RU93048868A
RU93048868A RU93048868/14A RU93048868A RU93048868A RU 93048868 A RU93048868 A RU 93048868A RU 93048868/14 A RU93048868/14 A RU 93048868/14A RU 93048868 A RU93048868 A RU 93048868A RU 93048868 A RU93048868 A RU 93048868A
Authority
RU
Russia
Prior art keywords
fatty acids
levels
disorders
viral diseases
infectious viral
Prior art date
Application number
RU93048868/14A
Other languages
Russian (ru)
Other versions
RU2112517C1 (en
Inventor
Фредерик Хорробин Дэвид
Энн Скотт Кэтрин
Original Assignee
Скотиа Холдингс ПЛС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929218064A external-priority patent/GB9218064D0/en
Application filed by Скотиа Холдингс ПЛС filed Critical Скотиа Холдингс ПЛС
Publication of RU93048868A publication Critical patent/RU93048868A/en
Application granted granted Critical
Publication of RU2112517C1 publication Critical patent/RU2112517C1/en

Links

Claims (1)

Способ безопасного внутривенного введения жирной кислоты (или жирных кислот), в частности главных жирных кислот ряда н-6 и н-3 и конъюгированных жирных кислот заключается в том, что указанную жирную кислоту или жирные кислоты или их часть вводят в виде литиевых солей. Уровни лития в плазме во избежание гемолиза регулярно контролируют, поддерживая эти уровни предпочтительно не выше 0,7 мМ в течение длительного времени, предпочтительно не выше 0,4-0,5 мМ в первые 24-48 ч, либо поддерживая эти уровни на значении, составляющем определенную часть от указанных значений уровней, в том случае, если в виде литиевых солей вводится лишь часть от используемых жирных кислот. Этот способ может быть использован для лечения рака, инфекционных вирусных заболеваний и других нарушений, требующих поддержания высоких уровней жирных кислот в плазме.The method of safe intravenous administration of fatty acids (or fatty acids), in particular the main fatty acids of the n-6 and n-3 series and conjugated fatty acids, is that said fatty acid or fatty acids or their part is administered as lithium salts. Plasma lithium levels are regularly monitored to avoid hemolysis, maintaining these levels preferably not higher than 0.7 mM for a long time, preferably not higher than 0.4-0.5 mM in the first 24-48 hours, or maintaining these levels at a value constituting a certain part of the indicated values of the levels, in the event that in the form of lithium salts only a part of the used fatty acids is introduced. This method can be used to treat cancer, infectious viral diseases and other disorders that require maintaining high levels of fatty acids in the plasma.
RU93048868A 1992-08-25 1993-08-24 Method of safety fatty acids administration, its use for cancer treatment, infectious viral diseases RU2112517C1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9218064.5 1992-08-25
GB9218064,5 1992-08-25
GB929218064A GB9218064D0 (en) 1992-08-25 1992-08-25 Method for the safe intravenous administration of fatty acids
GB9222654.7 1992-10-28

Publications (2)

Publication Number Publication Date
RU93048868A true RU93048868A (en) 1996-06-10
RU2112517C1 RU2112517C1 (en) 1998-06-10

Family

ID=10720932

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93048868A RU2112517C1 (en) 1992-08-25 1993-08-24 Method of safety fatty acids administration, its use for cancer treatment, infectious viral diseases

Country Status (6)

Country Link
US (1) US5508307A (en)
KR (1) KR940003544A (en)
GB (2) GB9218064D0 (en)
RU (1) RU2112517C1 (en)
TW (1) TW325404B (en)
ZA (1) ZA936233B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773300A (en) * 1995-05-18 1998-06-30 Cell Therapeutics, Inc. Neoplasia diagnostic method
US6166076A (en) * 1996-12-13 2000-12-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Taste enhancing food additives
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US6737078B1 (en) * 1999-11-24 2004-05-18 The Iams Company Process for enhancing canine and feline reproductive performance
US20050032897A1 (en) * 2000-11-22 2005-02-10 The Iams Company Process for enhancing canine and feline reproductive performance
JP5234450B2 (en) 2007-09-21 2013-07-10 独立行政法人農業・食品産業技術総合研究機構 Placenta stripping method using arachidonic acid derivatives, etc.
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2211881A4 (en) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
WO2016196894A1 (en) * 2015-06-03 2016-12-08 Kradl Therapeutics, Llc Compositions of polyunsaturated fatty acids and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2040847T3 (en) * 1987-04-27 1996-07-16 Efamol Holdings A PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION CONTAINING A LITHIUM SALT.
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
JPH0386819A (en) * 1989-04-27 1991-04-11 Nippon Oil & Fats Co Ltd Vascularization suppressing agent

Similar Documents

Publication Publication Date Title
CA2142314A1 (en) Method of Reducing Blood Levels of Total Cholesterol and Low-Density Lipoprotein Cholesterol
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
KR930001902A (en) Method for preparing fatty acid drug
KR950701350A (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES WITH INTERFERON WHILE REDUCING SIDE EFFECTS
ES2032382T3 (en) METHOD FOR PREPARING A MEDICATION FOR THE PREVENTION OR TREATMENT OF ENDOMETRIOSIS.
RU93048868A (en) METHOD FOR SAFE INTRODUCTION OF FATTY ACIDS, ITS APPLICATION FOR THE TREATMENT OF CANCER, INFECTIOUS VIRAL DISEASES AND OTHER DISORDERS
DE68926115D1 (en) METHOD FOR TREATING ACNE
DE69424777D1 (en) 3,4-DIARYLCHROMANE FOR TREATING DERMATITIS
TW325404B (en) Pharmaceutical composition for the safe administration of fatty acids the invention relates to a pharmaceutical composition for the safe administration of fatty acids which is useful in the treatment of cancer, viral infections and other disorders.
IT1255968B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING URSODESOXICOLIC ACID
JPH072663A (en) Virus infection remedy
Tavenner Use of tranexamic acid in control of haemorrhage after extraction of teeth in haemophilia and Christmas disease
KR910005858A (en) Fatty acid therapy
MX9301922A (en) COMPOSITIONS FOR THE TREATMENT OF INFECTION AND DISEASE CAUSED BY THE VIRUS OF HEPATITIS B (HBV).
NO933016L (en) Procedure for the safe administration of fatty acid
ATE92756T1 (en) MEANS FOR TREATMENT OF KERATosis.
KR900701278A (en) Bile acids for the treatment of viral infections
FR2707880B1 (en) Pharmaceutical compositions and their use, in particular for the treatment of neurodegenerative diseases.
KR890009868A (en) Trometamine salt of 1-methyl-β-oxo-α- (phenylcarbamoyl) -2-pyrrolepropionitrile
FR2561919B1 (en) PHARMACEUTICAL COMPOSITION CONSTITUTED ON THE ONE HAND, AS ACTIVE INGREDIENT, BY 9A, 11B-DICHLORO 16A-METHYL 21-OXYCARBONYLDICYCLOHEXYL METHYLOXY PREGNA-1,4-DIENE 3,20-DIONE AND ON THE OTHER HAND, BY A PHARM EXCIPIENT INERTE CAPABLE OF ALLOWING THE ACTION OF THE PRODUCT IN THE RECTUM OR THE COLON
FR2616327B3 (en) MIXTURE OF MEDICINAL PLANTS AS A MEDICAMENT FOR THE TREATMENT OF ULCERS AND CHRONIC GASTRITES
Miller et al. Effect of penicillin dosage schedule on treatment of experimental typhoid infections in mice
SU1227005A1 (en) Immunostimulator t-lymphocyte in treating neuroallergic disease
RU2071342C1 (en) Method of treatment of cirrhotic form of lung tuberculosis
RU1822775C (en) Method for treatment of trigeminal nerve neuralgia